Noopept Powder

Noopept Powder

Noopept

• CAS Number: 157115-85-0
• Molar Mass: 318.373 g·mol−1
• Chemical Formula: C17H22N2O4
• IUPAC Name: Ethyl 1-(phenylacetyl)-L-prolylglycinate

Introduction

Noopept Powder is a meticulously formulated research product explicitly designed for scientific exploration and not intended for human consumption. This powder form of Noopept serves as a valuable tool for researchers investigating its unique properties and potential benefits in various research domains.

Key Characteristics

Noopept is a nootropic compound known for its cognitive-enhancing effects. It is recognized for its potential neuroprotective properties and has become a focus of research in the field of neuroscience.

Research Applications

Noopept Powder has versatile applications in research, providing researchers with a tool to explore its potential benefits. Its applications extend to investigations into cognitive disorders, neuroprotection, and metabolic health.

Research Benefits

Cognitive Disorders

Studies suggest that Noopept may have applications in addressing cognitive disorders. Research in this domain aims to understand its mechanisms of action and potential therapeutic applications for cognitive impairment.

Neuroprotection

Preliminary research indicates that Noopept may have neuroprotective properties, potentially influencing neuronal survival and function. Investigations into its effects on protecting the brain from damage contribute to understanding its potential applications in neuroprotection.

Diabetes

Research suggests that Noopept may affect diabetes by influencing glucose metabolism. Studies exploring its effects on diabetes-related parameters contribute to understanding its potential applications in metabolic health.

Summary

Noopept Powder, developed exclusively for research purposes, provides researchers with a unique avenue for investigating its potential benefits in cognitive disorders, neuroprotection, and metabolic health. The distinctive characteristics of Noopept make it a promising subject for further exploration in neuroscientific and metabolic research.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to our Terms and Conditions. Customer satisfaction stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE:

All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

• Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol. 2009 Mar;39(3):311-21. doi: 10.1007/s11055-009-9128-4. PMID: 19234797. [Read More]
• Ostrovskaya RU, Vakhitova YV, Kuzmina USh, Salimgareeva MKh, Zainullina LF, Gudasheva TA, Vakhitov VA, Seredenin SB. The neuroprotective effect of novel cognitive enhancer Noopept on an AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. J Biomed Sci. 2014 Aug 6;21(1):74. doi: 10.1186/s12929-014-0074-2. PMID: 25096780; PMCID: PMC4422191. [Read More]
• Perihan Gürbüz, Halil Düzova, Azibe Yildiz, Pınar Çakan, Gül Büşra Kaya, Harika Gözde Gözükara Bağ, Merve Durhan, Cemile Ceren Gül, Aslı Çetin Taşlidere. Effects of Noopept on cognitive functions and pubertal process in rats with diabetes. Life Sciences, Volume 233, 2019, 116698, ISSN 0024-3205. https://doi.org/10.1016/j.lfs.2019.116698. [Read More]